Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Kaltura Inc (KLTR) Price & Performance

Gilead Sciences, Inc.Trade
Kaltura IncTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Kaltura Inc — how do they compare? Gilead Sciences, Inc. trades at $135.89 (market cap $164.99B), while Kaltura Inc trades at $1.64 (market cap $250.18M). The key difference: Gilead Sciences, Inc. is far larger — about 659.5× Kaltura Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Kaltura Inc pays none. Which is the better fit depends on your goals.

GILDKLTR
Market Cap
$164.99B$250.18M
Sector
HealthTechnology
52-Week High
$155.80$1.89
52-Week Low
$110.56$1.08
Enterprise Value
$188.06B$262.40M
Dividend Yield
2.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.

The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.

Kaltura Inc

Kaltura (KLTR) trades at $1.75, up 1.74% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue is stable around $181M, but the company remains unprofitable with a net margin of -6.92%. Positive cash flow from operations and industry recognitions for AI and video platforms highlight growth potential, though high debt and insider selling pose concerns.

The outlook is mixed: analyst consensus leans buy (44% buy ratings) on AI innovation and cash flow improvements, but risks include persistent losses, elevated valuation ratios, and competitive pressures. Investors should weigh cost control progress against profitability challenges for upside.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Kaltura Inc

Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)

Read more on KLTR